{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:04:24Z","timestamp":1767841464033,"version":"3.49.0"},"reference-count":55,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Oligometastatic cancer is recognized as a separate entity within the spectrum of metastatic disease. It was suggested that patients with oligometastatic disease can obtain long-term survival by giving local ablative therapy (LAT) to all visible disease locations. However, the true extent from which metastatic cancer should be called \u201coligometastatic\u201d is unknown, although a consensus definition for oligometastatic disease is proposed by research organizations, such as the EORTC (maximum of five metastases in three organs). Different states of the oligometastatic disease are defined, such as synchronous vs. metachronous, oligopersistent vs. oligoprogressive disease. All clinical trials including patients with non-small cell lung cancer (NSCLC) are small and most are not randomized. Two small randomized phase II trials on synchronous disease showed an improvement in progression free survival, with the addition of LAT, and one also demonstrated an overall survival benefit. Immune checkpoint inhibitors (ICI) were not part of the treatment in these trials, while ICI significantly improved long-term outcomes of patients with metastatic NSCLC. Radiotherapy might improve the prognosis of patients treated with ICI because of its immunostimulatory effects and the possibility to eradicate metastatic deposits. Here, we summarize the data for adding ablative radiotherapy to the treatment of oligometastatic NSCLC, especially in the ICI era, and discuss the challenges of combined treatment.<\/jats:p>","DOI":"10.3390\/cancers13092132","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T10:41:58Z","timestamp":1619606518000},"page":"2132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?"],"prefix":"10.3390","volume":"13","author":[{"given":"Stephanie T. H.","family":"Peeters","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), Maastricht University Medical Center, GROW, 6229 ET Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evert J.","family":"Van Limbergen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), Maastricht University Medical Center, GROW, 6229 ET Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, GROW\u2013School for Oncology and Developmental Biology, Maastricht University Medical Center, 6229 ET Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology (MAASTRO), Maastricht University Medical Center, GROW, 6229 ET Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Non-Small Cell Lung Cancer Collaborative Group (2010). Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst. Rev., 12, CD007309."},{"key":"ref_3","first-page":"CD002143","article-title":"Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer","volume":"1","author":"Stevens","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2284","article-title":"LBA51\u2014KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) \u226550%","volume":"31","author":"Brahmer","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20170157","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: The past, the present and the future","volume":"90","author":"Marcus","year":"2017","journal-title":"Br. J. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2019.07.025","article-title":"Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report","volume":"14","author":"Dingemans","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-Term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/JTO.0b013e318262caf6","article-title":"Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Long-term results of a prospective phase II trial (Nct01282450)","volume":"7","author":"Wanders","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jtho.2018.07.098","article-title":"Progression-Free survival and overall survival beyond 5 years of NSCLC patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450)","volume":"13","author":"Wanders","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.lungcan.2019.02.006","article-title":"Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study","volume":"130","author":"Arrieta","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-Term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data meta-analysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.ejca.2015.08.008","article-title":"Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study","volume":"51","author":"Hendriks","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ijrobp.2019.10.038","article-title":"Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: Translational correlatives from a mature randomized phase II trial","volume":"106","author":"Tang","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radio-therapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","article-title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study","volume":"152","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year overall survival for patients with advanced non small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-Year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non\u2013small cell lung cancer a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Theelen, W.S.M.E., Chen, D., Verma, V., Hobbs, B.P., Peulen, H.M.U., Aerts, J.G.J.V., Bahce, I., Niemeijer, A.L.N., Chang, J.Y., and de Groot, P.M. (2020). Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Respir. Med.","DOI":"10.1016\/S2213-2600(20)30391-X"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0039-3400290","article-title":"Local ablative therapies in oligometastatic NSCLC: New data and new directions","volume":"41","author":"Lang","year":"2020","journal-title":"Semin Respir. Crit. Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rheinheimer, S., Heussel, C.P., Mayer, P., Gaissmaier, L., Bozorgmehr, F., Winter, H., Herth, F.J., Muley, T., Liersch, S., and Bischoff, H. (2020). Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors. Cancers, 12.","DOI":"10.3390\/cancers12041046"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1111\/cas.14605","article-title":"Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer","volume":"111","author":"Kagawa","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2018.11.017","article-title":"Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis","volume":"126","author":"Petrelli","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.12.017","article-title":"Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study","volume":"128","author":"Gadgeel","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"MYSTIC investigators. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_35","unstructured":"(2021, February 23). Update on the Phase III NEPTUNE Trial of Imfinzi Plus Tremelimumab in Stage IV Non-Small Cell Lung Cancer. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/update-on-the-phase-iii-neptune-trial-of-imfinzi-plus-tremelimumab-in-stage-iv-non-small-cell-lung-cancer-21082019.html."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lussier, Y.A., Khodarev, N.N., Regan, K., Corbin, K., Li, H., Ganai, S., Khan, S.A., Gnerlich, J.L., Darga, T.E., and Fan, H. (2012). Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050141"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Faivre-Finn, C., Vicente, D., Kurata, T., Planchard, D., Paz-Ares, L., Vansteenkiste, J.F., Spigel, D.R., Garassino, M.C., Reck, M., and Senan, S. (2021). Four-Year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J. Thorac. Oncol.","DOI":"10.1016\/j.jtho.2020.12.015"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1832760","DOI":"10.1080\/2162402X.2020.1832760","article-title":"Immunotherapy as sensitizer for local radiotherapy","volume":"9","author":"Vanneste","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/ni.2705","article-title":"Tissue-resident macrophages","volume":"14","author":"Davies","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Botticelli, A., Cirillo, A., Scagnoli, S., Cerbelli, B., Strigari, L., Cortellini, A., Pizzuti, L., Vici, P., De Galitiis, F., and Di Pietro, F.R. (2020). The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy. Vaccines, 8.","DOI":"10.3390\/vaccines8020203"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Young, K.H., Baird, J.R., Savage, T., Cottam, B., Friedman, D., Bambina, S., Messenheimer, D.J., Fox, B., Newell, P., and Bahjat, K.S. (2016). Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157164"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.21037\/jtd-2019-cptn-07","article-title":"Radiation and immunotherapy: Emerging mechanisms of synergy","volume":"12","author":"Breen","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: Building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: Mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S1470-2045(19)30157-3","article-title":"Integration of radiotherapy and immunotherapy for treatment of oligometastases","volume":"20","author":"Pitroda","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/0218492309338100","article-title":"Impact of video-assisted thoracoscopic major lung resection on immune function","volume":"17","author":"Ng","year":"2009","journal-title":"Asian Cardiovasc. Thorac. Ann."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/9\/2132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:54:48Z","timestamp":1760162088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/9\/2132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":55,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cancers13092132"],"URL":"https:\/\/doi.org\/10.3390\/cancers13092132","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]}}}